OR WAIT null SECS
Ellicott City, MD, April 11, 2016 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced that Medpace will participate as a Global Impact Partner (GIP) and align with 34 other sponsors, CROs, and service providers dedicated to promoting high-level communication and meaningful collaboration between industry stakeholders and clinical research sites globally. “Medpace is pleased to be a Global Impact Partner with SCRS,” said Susan E. Burwig, Medpace Senior Vice President, Operations. “Investigational sites continue to drive the success of our industry. Medpace - a CRO noted for quality deliverables - believes we can successfully work with other SCRS members to enhance site relationships to the benefit of all stakeholders.” “SCRS is proud to partner with Medpace,” said SCRS President, Christine Pierre. “Collaboration with leading organizations across the clinical research landscape is a critical strategic development for SCRS to realize its mission in supporting sites. This commitment by Medpace speaks to their strong desire to collaborate with the sites perspective and we are pleased to welcome them to SCRS.” As a Global Impact Partner (GIP), Medpace will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS. About SCRS SCRS is a global trade organization founded in 2012 which represents over 2,600 research sites in 42 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org. About Medpace Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious diseases and vaccines, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2,400 employees and has clinical trial experience in over 50 countries and 6 regions – North America, Europe, Asia Pacific, Latin America, Africa, and the Middle East. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management. For more information visit the Medpace website at: www.medpace.com.